| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-078 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于公司非独立董事辞职暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事离任情况 浙江华康药业股份有限公司（以下简称"公司"）董事会于近日收到非独立 董事杜勇锐先生提交的书面辞职报告，因公司内部工作调整，杜勇锐先生申请辞 去公司第六届董事会非独立董事职务，辞职后仍继续在公司担任其他职务。具体 情况如下： (一)提前离任的基本情况 | 姓名 | 离任职 | 离任时 | | 原定任期 | | | | 是否继续在上 | 具体职务 | | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 务 | 间 | | 到期日 | | | 离任原因 | 市公司及其控 股子公 ...

贵公司已向本所承诺：贵公司向本所律师所提供的文件和所作陈述及说明是 完整的、真实的和有效的，有关原件及其上面的签字和印章是真实的，且一切足 以影响本法律意见书的事实和文件均已向本所披露，无任何隐瞒、疏漏之处。 在本法律意见书中，本所律师根据《股东会规则》的要求，仅就本次股东大 会的召集、召开程序是否合法及是否符合《公司章程》、出席会议人员资格和会 议召集人资格的合法有效性、会议表决程序和表决结果的合法有效性发表意见， 而不对本次股东大会所审议的议案内容和该等议案中所表述的事实或数据的真 实性和准确性发表意见。 本所律师仅根据本法律意见书出具日前发生或存在的事实及有关的法律、行 政法规、规范性文件及《公司章程》的规定发表法律意见。本法律意见书仅供本 次股东大会之目的而使用，不得用于其他任何目的或用途。本所同意，贵公司可 以将本法律意见书作为贵公司本次股东大会公告材料，随其他需公告的信息一起 国浩律师（杭州）事务所（以下简称"本所"）接受贵公司的委托，指派本 所律师出席贵公司于 2025 年 9 月 8 日在浙江省衢州市开化县华埠镇华工路 18 号公司四楼会议室召开的 2025 年第二次临时股东大会（以下简称"本 ...

| 证券代码：605077 | 证券简称：华康股份 公告编号：2025-077 | | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | 浙江华康药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 8 日 (二)股东大会召开的地点：浙江省衢州市开化县华埠镇华工路 18 号公司四 楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 161 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 118,561,507 | | 3、出席会议的股东所持有表决权股份数占公司有表决权 | 39.1227 | | 股份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 表决情况： 本次股东大会由公司董 ...

Core Viewpoint - Huakang Co., Ltd. announced the early return of 50 million yuan of idle raised funds to the special account for raised funds, which will be completed by September 4, 2025 [2] Group 1 - The company will return all idle raised funds used for temporary working capital [2] - The total amount being returned is 50 million yuan [2] - The deadline for the return is set for September 4, 2025 [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开了 第六届董事会第三十一次会议和第六届监事会第二十次会议，审议通过了《关于 使用部分闲置募集资金临时补充流动资金的议案》，同意公司使用 2021 年首次 公开发行股票闲置募集资金不超过 5,000 万元（含 5,000 万元）用于临时补充流 动资金，使用期限为公司第六届董事会第三十一次会议审议通过之日起不超过 12 个月。具体详见公司于 2025 年 4 月 28 日在上海证券交易所网站（www.sse.com.cn） 披露的《华康股份关于使用部分闲置募集资金临时补充流动资金的公告》（编号： 2025-051）。 截至 2025 年 9 月 4 日，公司提前将实际用于临时补充流动资金的闲置募集 资金 5,000 万元全部归还至募集资金专用账户，同时，公司已将上述归还情况通 知了保荐机构及保荐代表人。 特此公告。 浙江华康药业股份有限公司 董事会 2025 年 9 月 5 日 | 证券代码：60 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report suggests a focus on potential profit recovery and monitoring of key factors affecting profitability [1][3]. Core Views - The company's revenue for the first half of 2025 reached 1.866 billion yuan, a year-on-year increase of 37.32%, while the net profit attributable to shareholders was 134 million yuan, a decrease of 3.38% year-on-year [1]. - The second quarter of 2025 saw a revenue of 1.049 billion yuan, up 44.95% year-on-year, but the net profit attributable to shareholders was 52.67 million yuan, down 9.79% year-on-year [1][3]. - The company is experiencing short-term profit pressure due to changes in product structure and increased costs associated with the new production line in Zhoushan [3]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved total revenue of 1.866 billion yuan, with a year-on-year growth of 37.32%. The net profit attributable to shareholders was 134 million yuan, reflecting a decline of 3.38% year-on-year [1]. - For Q2 2025, the company reported revenue of 1.049 billion yuan, representing a 44.95% increase year-on-year, while the net profit attributable to shareholders was 52.67 million yuan, down 9.79% year-on-year [1][3]. Product and Project Developments - The Zhoushan production line is gradually coming online, contributing to significant revenue growth in Q2. The first phase of the "1 million tons corn deep processing health food ingredient project" has been completed and is in production [3]. - The company’s product mix has shifted, impacting gross margins, with Q2 gross margin at 16.56%, down 3.00 percentage points year-on-year [3]. Profitability Outlook - The report indicates that profit is under short-term pressure due to the impact of the Zhoushan project and the capitalization of convertible bond interest expenses. However, there is potential for profit recovery if the price of xylitol reverses and if production capacity utilization improves [3]. - The projected earnings per share (EPS) for 2025-2027 are 0.84, 1.23, and 1.73 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 23X, 16X, and 11X [3].

Core Points - The company is holding a shareholders' meeting to discuss various proposals and ensure the rights of shareholders are protected [1][2] - The meeting will include discussions on profit distribution, cancellation of the supervisory board, and amendments to the company's articles of association [6][9][11] Group 1: Meeting Procedures - The company will manage the agenda and logistics of the shareholders' meeting, and attendees must comply with the arrangements [1] - Only authorized personnel, including shareholders and their representatives, will be allowed to enter the meeting venue [1] - Shareholders must arrive 15 minutes before the meeting to complete registration and present necessary documentation [1][2] Group 2: Shareholder Participation - Shareholders wishing to speak must register 10 minutes before the meeting starts and will have a limited time to present their views [2] - The meeting host will call on shareholders to speak, and each speaker must state their shareholding details before presenting their opinions [2] - Questions unrelated to the meeting agenda or that may harm the company's interests can be refused by the meeting host [2] Group 3: Proposals - Proposal 1: The company plans to distribute a cash dividend of 2 yuan per 10 shares, with a profit distribution ratio of 45.33% based on the net profit as of June 30, 2025 [6] - Proposal 2: The company will abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, in compliance with new regulations [6][9] - Proposal 3: The company aims to revise its internal management systems to enhance governance, aligning with updated legal requirements [9][10] - Proposal 4: The company intends to conclude certain fundraising projects and permanently allocate the remaining funds to supplement working capital [11]

浙江华康药业股份有限公司 2025 年第二次临时股东大会 会议材料 二○二五年九月 2025 年第二次临时股东大会 浙江华康药业股份有限公司 2025 年第二次临时股东大会会议须知 一、公司负责本次股东大会的议程安排和会务工作，出席会议人员应当听从 公司工作人员安排，共同维护好会议秩序。 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权 利，根据《公司法》、中国证监会《上市公司股东大会规则》和公司《股东大会 议事规则》等有关规定，特制定本会议须知： 二、为保证股东大会的正常秩序，除出席会议的股东或者股东代理人、董事、 监事、高级管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他 人员进入会场。 三、出席会议的股东须在会议召开前 15 分钟到达会议现场向公司会务人员 办理签到手续，并请按规定出示股票账户卡、持股凭证、身份证或法人单位证明、 授权委托书及出席人身份证等，经验证后领取会议资料，方可出席会议。 四、股东需要在股东大会发言的，应于会议开始前 10 分钟向公司会务人员 进行登记，出示有效的持股证明，填写《发言登记表》；全部股东发言时间控制 在 30 分钟以内，登记后的发言顺序按其 ...

Group 1 - A-shares experienced a decline in most major indices on August 26, with the Tianhong Food and Beverage ETF (159736) showing a slight increase of 0.13% during trading [1] - The Tianhong Food and Beverage ETF has seen a net inflow of funds for five consecutive days, accumulating 86.54 million yuan, with a net inflow of 9.03 million yuan on the previous day [1] - The ETF closely tracks the CSI Food and Beverage Index, which includes major companies in the beverage, packaged food, and meat sectors, with top holdings including Kweichow Moutai, Yili, and Wuliangye [1] Group 2 - In the first half of 2025, China's retail sales of consumer goods reached 24.55 trillion yuan, a year-on-year increase of 5.0%, with restaurant revenue at 2.75 trillion yuan, up 4.3% [2] - Among 231 listed companies in the food and beverage sector, 82 have reported their first-half 2025 earnings, with total revenue of 550.84 billion yuan, a 7.12% increase year-on-year, and net profit of 82.13 billion yuan, up 15.30% [2] - The overall trend in the food and beverage industry indicates stable growth in both revenue and profit, with a focus on the performance of snack brands and the recovery of consumer confidence [2]

Group 1 - The core viewpoint of the article highlights a significant surge in the sugar substitute concept stocks, with notable performances from several companies [1] Group 2 - Zhonghua International experienced a limit-up increase in its stock price [1] - Baolingbao saw an increase of over 5% in its stock price [1] - Huakang Co., Bailong Chuangyuan, and Xinghuo Technology also experienced upward movements in their stock prices [1]